Horizon Pharma
Horizon buys out Raptor for $800 million
September 13, 2016Manufacturing and Production, Sales and Marketing Horizon Pharma, Raptor Pharmaceutical, acquisition
Irish biopharmaceutical firm Horizon Pharma has finalised an $800 million deal to buy Raptor Pharmaceutical Corp in a bid to …
Horizon receives European go-ahead for Ravicti
December 2, 2015Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders
The European Commission has approved Ravicti for rare urea cycle disorders. Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
Horizon Pharma receives third rejection from Depomed
August 21, 2015Sales and Marketing Depomed, Horizon Pharma, pharma mergers and acquisitions
Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy the California-based company. Following its …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
